Motivations behind complementary and alternative medicine use in patients with Crohn's disease and ulcerative colitis.
Journal
Journal of the Canadian Association of Gastroenterology
ISSN: 2515-2092
Titre abrégé: J Can Assoc Gastroenterol
Pays: England
ID NLM: 101738684
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
17
10
2024
Statut:
epublish
Résumé
Complementary and alternative medicine (CAM) use is common in inflammatory bowel disease (IBD) patients and impacts compliance with conventional treatment. Gastroenterologists should understand the motivational factors of CAM use-factors that Retrospective cohort survey of patients over 18 years old with IBD, evaluated by gastroenterologists at a tertiary care referral centre from January 1 to December 31, 2019. Only patients who reported CAM use were included. Chi-square and independent Of the 230 completed surveys, 193 reported CAM use (CD: 57.5% vs UC: 42.5%). Demographics, disease duration, and hospitalizations were similar, but CD patients had lower SIBDQ scores (CD: 48.1 vs UC: 53.5, Despite differences in QoL, push and pull motivations for CAM use did not differ between CD and UC patients. Most users do not feel well informed of CAM and ongoing dialogue is important for patient-centred care.
Sections du résumé
Background
UNASSIGNED
Complementary and alternative medicine (CAM) use is common in inflammatory bowel disease (IBD) patients and impacts compliance with conventional treatment. Gastroenterologists should understand the motivational factors of CAM use-factors that
Methods
UNASSIGNED
Retrospective cohort survey of patients over 18 years old with IBD, evaluated by gastroenterologists at a tertiary care referral centre from January 1 to December 31, 2019. Only patients who reported CAM use were included. Chi-square and independent
Results
UNASSIGNED
Of the 230 completed surveys, 193 reported CAM use (CD: 57.5% vs UC: 42.5%). Demographics, disease duration, and hospitalizations were similar, but CD patients had lower SIBDQ scores (CD: 48.1 vs UC: 53.5,
Conclusion
UNASSIGNED
Despite differences in QoL, push and pull motivations for CAM use did not differ between CD and UC patients. Most users do not feel well informed of CAM and ongoing dialogue is important for patient-centred care.
Identifiants
pubmed: 39416725
doi: 10.1093/jcag/gwae020
pii: gwae020
pmc: PMC11477972
doi:
Types de publication
Journal Article
Langues
eng
Pagination
376-383Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
Déclaration de conflit d'intérêts
N.K., R.T., and G.A. have no conflicts of interest. B.B. has served as an advisor/speaker/consultant for Pfizer, Merck, Ferring, Janssen, AbbVie, Takeda, Celgene, Genentech, Novartis, Amgen, Allergan, AMT, Fresenius Kabi, Gilead, Protagonist, Sandoz, Alimentiv, Iterative Scopes, Mylan and BMS; received research support from Janssen, AbbVie, Takeda, Atlantic Pharmaceuticals, GSK, BMS, Amgen, Genentech, Merck, RedHill Biopharma, BI, Qu Biologics, Celgene and Alvine; and had stock options in Qu Biologics. G.R. has served as an advisor/ speaker/ consultant for AbbVie, Ferring Fresnius, Kabi, Janssen, Merck, Pfizer, Eli-Lilly, and Takeda. Y.L. has served as advisor/speaker/consultant for Abbvie, Eli Lilly, Takeda, Bristol Myers, Squibb, Pendopharm, Organon, BioJamp, Janssen, Pfizer, and Amgen. In addition to this COI statement, ICMJE disclosure forms have been collected for all co-authors and can be accessed as supplementary material.